|
|
 Previous Article | Table of Contents | Next Article 
Mutations in N-ras predominate in acute myeloid leukemia
JL Bos, M Verlaan-de Vries, AJ van der Eb, JW Janssen, R Delwel, B Lowenberg and LP Colly
Using synthetic oligomers we investigated fresh samples of acute myeloid
leukemia (AML) for the presence of mutated ras oncogenes. Our original
results showed that five of eight samples contained a mutation in codon 13
of the N-ras gene. In a subsequent study involving 37 samples, we found
only one N-ras-13 mutation, and, in addition, mutations in codon 61 of the
N-ras gene in four cases and a mutation in codon 12 of the Ki-ras gene in
two cases. Amplification of ras genes was not observed. We conclude that in
approximately 20% to 25% of AML cases, a mutated ras oncogene is present,
predominantly the N-ras gene. The occurrence of mutations does not
correlate with the cytological features of the leukemia.
Volume 69,
Issue 4,
pp. 1237-1241,
04/01/1987
Copyright © 1987 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Neubauer, K. Maharry, K. Mrozek, C. Thiede, G. Marcucci, P. Paschka, R. J. Mayer, R. A. Larson, E. T. Liu, and C. D. Bloomfield
Patients With Acute Myeloid Leukemia and RAS Mutations Benefit Most From Postremission High-Dose Cytarabine: A Cancer and Leukemia Group B Study
J. Clin. Oncol.,
October 1, 2008;
26(28):
4603 - 4609.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. M. Loriaux, R. L. Levine, J. W. Tyner, S. Frohling, C. Scholl, E. P. Stoffregen, G. Wernig, H. Erickson, C. A. Eide, R. Berger, et al.
High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia
Blood,
May 1, 2008;
111(9):
4788 - 4796.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. M. Van Meter, E. Diaz-Flores, J. A. Archard, E. Passegue, J. M. Irish, N. Kotecha, G. P. Nolan, K. Shannon, and B. S. Braun
K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells
Blood,
May 1, 2007;
109(9):
3945 - 3952.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Bacher, T. Haferlach, C. Schoch, W. Kern, and S. Schnittger
Implications of NRAS mutations in AML: a study of 2502 patients
Blood,
May 15, 2006;
107(10):
3847 - 3853.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Okudela, H. Hayashi, T. Ito, T. Yazawa, T. Suzuki, Y. Nakane, H. Sato, H. Ishi, X. KeQin, A. Masuda, et al.
K-ras Gene Mutation Enhances Motility of Immortalized Airway Cells and Lung Adenocarcinoma Cells via Akt Activation: Possible Contribution to Non-Invasive Expansion of Lung Adenocarcinoma
Am. J. Pathol.,
January 1, 2004;
164(1):
91 - 100.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. C. Platanias
Map kinase signaling pathways and hematologic malignancies
Blood,
June 15, 2003;
101(12):
4667 - 4679.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R.K. WILSON, T.J. LEY, F.S. COLE, J.D. MILBRANDT, S. CLIFTON, L. FULTON, G. FEWELL, P. MINX, H. SUN, M. MCLELLAN, et al.
Mutational Profiling in the Human Genome
Cold Spring Harb Symp Quant Biol,
January 1, 2003;
68(0):
23 - 30.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G. W. Reuther, Q. T. Lambert, J. F. Rebhun, M. A. Caligiuri, L. A. Quilliam, and C. J. Der
RasGRP4 Is a Novel Ras Activator Isolated from Acute Myeloid Leukemia
J. Biol. Chem.,
August 16, 2002;
277(34):
30508 - 30514.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Karp, J. E. Lancet, S. H. Kaufmann, D. W. End, J. J. Wright, K. Bol, I. Horak, M. L. Tidwell, J. Liesveld, T. J. Kottke, et al.
Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial
Blood,
June 1, 2001;
97(11):
3361 - 3369.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. R. Appelbaum, J. M. Rowe, J. Radich, and J. E. Dick
Acute Myeloid Leukemia
Hematology,
January 1, 2001;
2001(1):
62 - 86.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. W. Reuther, Q. T. Lambert, M. A. Caligiuri, and C. J. Der
Identification and Characterization of an Activating TrkA Deletion Mutation in Acute Myeloid Leukemia
Mol. Cell. Biol.,
December 1, 2000;
20(23):
8655 - 8666.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
C. W. M. Reuter, M. A. Morgan, and L. Bergmann
Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?
Blood,
September 1, 2000;
96(5):
1655 - 1669.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Guillaume, D. B. Rubinstein, and M. Symann
Immune Reconstitution and Immunotherapy After Autologous Hematopoietic Stem Cell Transplantation
Blood,
September 1, 1998;
92(5):
1471 - 1490.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Yan, M.-x. Chen, M. Perucho, and E. Friedman
Oncogenic Ki-ras but Not Oncogenic Ha-ras Blocks Integrin beta 1-Chain Maturation in Colon Epithelial Cells
J. Biol. Chem.,
December 5, 1997;
272(49):
30928 - 30936.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Jucker, C. A. Schiffer, and R. A. Feldman
A Tyrosine-Phosphorylated Protein of 140 kD Is Constitutively Associated With the Phosphotyrosine Binding Domain of Shc and the SH3 Domains of Grb2 in Acute Myeloid Leukemia Cells
Blood,
March 15, 1997;
89(6):
2024 - 2035.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Cline
The Molecular Basis of Leukemia
N. Engl. J. Med.,
February 3, 1994;
330(5):
328 - 336.
[Full Text]
|
|
|
|
|
